IL140884A0 - Novel dna cleaving antitumor agents - Google Patents

Novel dna cleaving antitumor agents

Info

Publication number
IL140884A0
IL140884A0 IL14088499A IL14088499A IL140884A0 IL 140884 A0 IL140884 A0 IL 140884A0 IL 14088499 A IL14088499 A IL 14088499A IL 14088499 A IL14088499 A IL 14088499A IL 140884 A0 IL140884 A0 IL 140884A0
Authority
IL
Israel
Prior art keywords
antitumor agents
novel dna
dna cleaving
cleaving
novel
Prior art date
Application number
IL14088499A
Other languages
English (en)
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL140884A0 publication Critical patent/IL140884A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL14088499A 1998-07-16 1999-07-16 Novel dna cleaving antitumor agents IL140884A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9311298P 1998-07-16 1998-07-16
PCT/US1999/016171 WO2000003709A1 (fr) 1998-07-16 1999-07-16 Nouveaux agents anticancer generant un clivage d'adn

Publications (1)

Publication Number Publication Date
IL140884A0 true IL140884A0 (en) 2002-02-10

Family

ID=22237206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14088499A IL140884A0 (en) 1998-07-16 1999-07-16 Novel dna cleaving antitumor agents

Country Status (12)

Country Link
US (1) US6908948B1 (fr)
EP (1) EP1109552A4 (fr)
JP (1) JP2002539071A (fr)
KR (1) KR100763211B1 (fr)
CN (1) CN1243545C (fr)
AU (1) AU762972B2 (fr)
CA (1) CA2337517A1 (fr)
IL (1) IL140884A0 (fr)
NZ (1) NZ509273A (fr)
RU (1) RU2227029C2 (fr)
WO (1) WO2000003709A1 (fr)
ZA (1) ZA200100353B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
RU2269356C2 (ru) * 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
TWI388280B (zh) * 2004-01-23 2013-03-11 Univ Pennsylvania 面上兩性之聚芳基和聚芳炔基聚合物與寡聚物及其用途
ES2369547T3 (es) 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
FR2914855A1 (fr) * 2007-04-13 2008-10-17 Oreal Composition comprenant au moins un derive substitue de carbocyanine acetylenique, procede de traitement des fibres keratiniques la mettant en oeuvre et dispositif
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN104513250B (zh) * 2014-12-23 2016-11-23 南开大学 一种水溶性卟啉的合成方法及其光催化应用
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
CN107095876B (zh) * 2017-05-24 2019-12-03 上海交通大学医学院 二苯基联烯基氧膦化合物在制备治疗肺癌药物中的应用
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098920A (en) * 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
US5767142A (en) * 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US6297284B1 (en) * 1998-07-16 2001-10-02 Research Development Foundation DNA-cleaving antitumor agents

Also Published As

Publication number Publication date
RU2227029C2 (ru) 2004-04-20
CA2337517A1 (fr) 2000-01-27
KR20010083116A (ko) 2001-08-31
EP1109552A1 (fr) 2001-06-27
JP2002539071A (ja) 2002-11-19
ZA200100353B (en) 2002-01-10
US6908948B1 (en) 2005-06-21
CN1313766A (zh) 2001-09-19
KR100763211B1 (ko) 2007-10-08
NZ509273A (en) 2003-05-30
AU762972B2 (en) 2003-07-10
EP1109552A4 (fr) 2007-11-07
WO2000003709A1 (fr) 2000-01-27
AU5108299A (en) 2000-02-07
CN1243545C (zh) 2006-03-01
WO2000003709A9 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
GB2338672B (en) Toolholder
GB9808145D0 (en) Assay
IL140884A0 (en) Novel dna cleaving antitumor agents
HK1049682B (zh) 內切-β-N-乙酰葡糖胺糖苷酶基因
DE69833112D1 (en) Rna polymerase
GB9817704D0 (en) Gene switch
GB9817909D0 (en) DNA constructs
GB9818931D0 (en) Photobioreactor
GB9809160D0 (en) Assay
EP1038957A4 (fr) Gene tsa305
EP0998924A4 (fr) Agents antineoplastiques
AU4513599A (en) Nucleotide sequence
IL140295A0 (en) Novel biocontrol agents
GB9724828D0 (en) Gene
GB9827585D0 (en) Assay method
GB2335889B (en) Car
GB9828848D0 (en) Dna
GB9806702D0 (en) Dna
GB9812822D0 (en) Dna
GB9818734D0 (en) Gene
GB9809753D0 (en) Gene
GB9817566D0 (en) Gene
CA83807S (en) Chisel
GB9717913D0 (en) Dna
GB9704070D0 (en) Dna

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees